These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 3237569)
1. Synthesis and antineoplastic effects of furo[3,4-d]pyrimidine derivatives. Machoń Z; Cieplik J Pol J Pharmacol Pharm; 1988; 40(2):201-8. PubMed ID: 3237569 [TBL] [Abstract][Full Text] [Related]
2. Efficient synthesis and biological evaluation of some 2,4-diamino-furo[2,3-d]pyrimidine derivatives. Hu YG; Wang Y; Du SM; Chen XB; Ding MW Bioorg Med Chem Lett; 2010 Nov; 20(21):6188-90. PubMed ID: 20850310 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological properties of 5-hydroxy-methylpyrimidines. Cieplik J; Machoń Z; Zimecki M; Wieczorek Z Arch Immunol Ther Exp (Warsz); 1993; 41(1):11-5. PubMed ID: 8239903 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor properties of pyrazolo [3,4-D] pyrimidine derivatives. Witkiewicz K; Machoń Z; Mordarski M; Wieczorek J Pol J Pharmacol Pharm; 1987; 39(6):715-20. PubMed ID: 3503990 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and pharmacological properties of derivatives of isoxazolo [5,4-d]-6,7-dihydropyrimidines. Machoń Z; Ryng S Pol J Pharmacol Pharm; 1988; 40(2):209-16. PubMed ID: 3237570 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and properties of 7-methyl-5-oxo-1,5-dihydro-8-[1,2,4]-triazolo [4,3-c]pyrimidinecarboxylic acid derivatives. Długosz A; Machoń Z; Jasztold-Howorko R Pharmazie; 1989 Sep; 44(9):604-5. PubMed ID: 2608705 [TBL] [Abstract][Full Text] [Related]
7. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines. Gangjee A; Adair O; Queener SF J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486 [TBL] [Abstract][Full Text] [Related]
8. Isothiazolopyrimidines--new group of anticancer agents. I. Machoń Z; Wieczorek J; Mordarski M Arch Immunol Ther Exp (Warsz); 1987; 35(5):599-607. PubMed ID: 3455649 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives. Gazivoda T; Sokcević M; Kralj M; Suman L; Pavelić K; De Clercq E; Andrei G; Snoeck R; Balzarini J; Mintas M; Raić-Malić S J Med Chem; 2007 Aug; 50(17):4105-12. PubMed ID: 17672445 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents. Gangjee A; Adair OO; Queener SF J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and cytotoxicity of the three-membered aromatic pyrimidine derivatives. Długosz A Acta Pol Pharm; 1997; 54(5):357-62. PubMed ID: 9584693 [TBL] [Abstract][Full Text] [Related]
12. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and cytotoxic evaluation of certain 4-(phenylamino)furo[2,3-b]quinoline and 2-(furan-2-yl)-4-(phenylamino)quinoline derivatives. Zhao YL; Chen YL; Tzeng CC; Chen IL; Wang TC; Han CH Chem Biodivers; 2005 Feb; 2(2):205-14. PubMed ID: 17191973 [TBL] [Abstract][Full Text] [Related]
15. In vitro cytotoxic activity of naphtho[1,2-b]furan, furo[2,3-f], furo[2,3-g] and furo[3,2-g]quinoline derivatives. Nebois P; Cherkaoui O; Benameur L; Boitard M; Bartoli MH; Fillion H Pharmazie; 1999 Mar; 54(3):215-8. PubMed ID: 10192109 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Hayakawa M; Kaizawa H; Moritomo H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Workman P; Waterfield MD; Parker P Bioorg Med Chem Lett; 2007 May; 17(9):2438-42. PubMed ID: 17339109 [TBL] [Abstract][Full Text] [Related]
17. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863 [TBL] [Abstract][Full Text] [Related]
18. Synthesis of novel trifluoromethyl substituted furo[2,3-b]pyridine and pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as potential anticancer agents. Naresh Kumar R; Poornachandra Y; Nagender P; Mallareddy G; Ravi Kumar N; Ranjithreddy P; Ganesh Kumar C; Narsaiah B Eur J Med Chem; 2016 Jan; 108():68-78. PubMed ID: 26629861 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and anticancer activity of 4-amino-5-oxo-8-(beta-D-xylofuranosyl)pyrido[2,3-d]pyrimidine. Pietrzkowski Z; Girardet JL; Esler C; Wang G Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):323-8. PubMed ID: 11563044 [TBL] [Abstract][Full Text] [Related]
20. Synthesis of some new pyrazolo[3,4-d]pyrimidine derivatives of expected anticancer and radioprotective activity. Ghorab MM; Ragab FA; Alqasoumi SI; Alafeefy AM; Aboulmagd SA Eur J Med Chem; 2010 Jan; 45(1):171-8. PubMed ID: 19853327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]